Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.29.

Several analysts have issued reports on VTYX shares. Oppenheimer cut their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, June 6th. Wells Fargo & Company cut their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. HC Wainwright reissued a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Tuesday, July 30th. Finally, Canaccord Genuity Group dropped their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th.

Ventyx Biosciences Stock Performance

NASDAQ VTYX opened at $1.96 on Wednesday. The business’s fifty day moving average is $2.41 and its two-hundred day moving average is $4.16. Ventyx Biosciences has a 1 year low of $1.84 and a 1 year high of $38.20. The stock has a market capitalization of $138.51 million, a P/E ratio of -0.60 and a beta of 0.39.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. On average, research analysts forecast that Ventyx Biosciences will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Ventyx Biosciences in the second quarter worth $32,000. Tower Research Capital LLC TRC boosted its holdings in Ventyx Biosciences by 1,424.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after purchasing an additional 18,620 shares in the last quarter. Federated Hermes Inc. bought a new stake in Ventyx Biosciences in the fourth quarter worth $50,000. The Manufacturers Life Insurance Company boosted its holdings in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Ventyx Biosciences in the second quarter worth $58,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.